2026 Prostate Cancer Guidelines: Screening, Diagnosis, and Curative Local Treatment Update

2026 prostate cancer guidelines: mpMRI to avoid unnecessary biopsies; PSMA PET for staging; active surveillance for low-risk/select favourable intermediate-risk; hypofractionated RT for intermediate-risk; cN1 → RT to primary + intensified hormonal therapy. Risk-adapted screening…

• A new five-tier EAU classification is introduced for prostate cancer risk assessment.
• Active surveillance is now appropriate for selected favourable intermediate-risk ISUP grade group 2 lesions.
• Combination of targeted and regional biopsies is recommended when biopsy is performed.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.